for inclusion in their TROPHY (Trial Of Preventing Hypertension) Study. Ten of the sub-study sites will utilize the HDI Instrument. The TROPHY Study will investigate whether early pharmacologic treatment of subjects with high normal blood pressure with Candesartan Cilexetil will prevent or delay the onset of clinical hypertension, a condition impacting 40 million Americans.

Jay N. Cohn, M.D., Professor of Medicine in the Cardiovascular Division at the University of Minnesota, advanced the concept of using arterial waveform analysis for monitoring blood vessel function in patients with hypertension and heart failure. He and his University colleague, Stanley M. Finkelstein, Ph.D., patented with the University, the methodology that led directly to the development of the CR-2000 Instrument. "The CR-2000 Instrument is an easy-to-use, sensitive and reproducible testing method for studying the effects of cardiovascular risk factors on subject’s arteries," says Dr. Cohn. "We hope eventually to provide the practicing physician with a simple office measurement that will identify the earliest stage of artery disease that is in need of treatment to prevent the consequences of heart attacks and strokes, which lead to more than half the deaths in the United States."

Hypertension Diagnostics has developed proprietary cardiovascular profiling technology that analyzes non-invasively derived arterial pulse pressure waveform data as a means of providing parameters that are useful in assessing the cardiovascular system. The Company has designed two models of the HDI/PulseWaveä CardioVascular Profiling Instrument: (1) the CR-2000 which is currently in use by physician scientists for research purposes only; and (2) the DO-2020 which is intended to assist physicians and other health care professionals in screening, diagnosing and monitoring the treatment of patients with cardiovascular disease. The Company has not yet received permission to market the DO-2020 from the Food and Drug Administration.

Forward-looking statements in this press release are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company wishes to caution readers not to place undue reliance on any forward-looking statements and to recognize that the statements are not predictions of actual future results. Actual results could differ materially from those anticipated in the forward-looking statements due to the risks and uncertainties set forth in the Company's 1998 Annual Report on Form 10-KSB under the caption "Risk Factors," as well as others not now anticipated. These risks and uncertainties include, without limitation, the Company's ability to receive regulatory approval for its Model DO-2020 product; the availability of third-party reimbursements; market acceptance of the Company's products; timely development of the Central Data Management Facility (CDMF); the ability of third parties to manufacture the Company's products on a commercial scale and in compliance with regulatory requirements; the availability of integral components for the Company's products; the Company's ability to develop distribution channels; increased competition; changes in government regulation; health care reform; exposure to potential product liability; and the Company's ability to protect its proprietary technology.

HDI/PulseWave is a trademark of Hypertension Diagnostics Inc.

Contact: Greg H. Guettler, President